U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H23ClN2.ClH
Molecular Weight 351.313
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOMIPRAMINE HYDROCHLORIDE

SMILES

Cl.CN(C)CCCN1C2=CC(Cl)=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=WIMWMKZEIBHDTH-UHFFFAOYSA-N
InChI=1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula C19H23ClN2
Molecular Weight 314.852
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Clomipramine is an antidepressant drug which was approved by FDA for the treatment of Obsessive-Compulsive Disorder. The exact mechanism of its action is unknown, however it is supposed that it may exert its effect by inhibiting serotonin reuptake.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANAFRANIL

Approved Use

Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Launch Date

1989
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
31.3 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
92 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
736 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOMIPRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Other AEs: Dry mouth, Constipation...
Other AEs:
Dry mouth (42.9%)
Constipation (25%)
Somnolence (24.1%)
Tremor (22.3%)
Dizziness (17.9%)
Nausea (16.1%)
Sweating (13.4%)
Asthenia (9.8%)
Insomnia (8%)
Abdominal pain (3.6%)
Sources:
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Other AEs: Somnolence, Tremor...
Other AEs:
Somnolence (46%)
Tremor (33%)
Dizziness (41%)
Headache (28%)
Insomnia (11%)
Nervousness (4%)
Myoclonus (2%)
Paresthesia (2%)
Memory impairment (7%)
Anxiety (2%)
Twitching (4%)
Hypertonia (2%)
Sleep disorder (9%)
Confusion (2%)
Depersonalization (2%)
Irritability (2%)
Panic reaction (2%)
Aggressive reaction (2%)
Paresis (2%)
Sweating increased (9%)
Rash (4%)
Pruritus (2%)
Skin odor abnormal (2%)
Dry mouth (63%)
Constipation (22%)
Nausea (9%)
Dyspepsia (13%)
Diarrhea (7%)
Anorexia (22%)
Abdominal pain (13%)
Vomiting (7%)
Eructation (2%)
Ulcerative stomatitis (2%)
Fatigue (35%)
Weight increase (2%)
Flushing (7%)
Hot flushes (2%)
Chest pain (7%)
Fever (2%)
Allergy (7%)
Pain (4%)
Weight decrease (7%)
Otitis media (4%)
Asthenia (2%)
Halitosis (2%)
Postural hypotension (4%)
Palpitation (4%)
Tachycardia (2%)
Syncope (2%)
Rhinitis (7%)
Sinusitis (2%)
Coughing (4%)
Bronchospasm (7%)
Dyspnea (2%)
Laryngitis (2%)
Micturition disorder (4%)
Urinary retention (7%)
Abnormal vision (7%)
Taste perversion (4%)
Tinnitus (4%)
Anisocoria (2%)
Blepharospasm (2%)
Eye allergy (2%)
Disorder vestibular (2%)
Muscle weakness (2%)
Anemia (2%)
Sources:
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Other AEs: Somnolence, Tremor...
Other AEs:
Somnolence (54%)
Tremor (54%)
Dizziness (54%)
Headache (52%)
Insomnia (25%)
Influence on libido (21%)
Nervousness (18%)
Myoclonus (13%)
Increased appetite (11%)
Paresthesia (9%)
Memory impairment (9%)
Anxiety (9%)
Twitching (7%)
Concentration impaired (5%)
Depression (5%)
Hypertonia (4%)
Sleep disorder (4%)
Psychosomatic disease (3%)
Yawning (3%)
Confusion (3%)
Speech disorder (3%)
Dreaming abnormal (3%)
Agitation (3%)
Migraine (3%)
Depersonalization (2%)
Irritability (2%)
Emotional lability (2%)
Panic reaction (1%)
Sweating increased (29%)
Rash (8%)
Pruritus (6%)
Dermatitis (2%)
Acne (2%)
Dry skin (2%)
Urticaria (1%)
Dry mouth (84%)
Constipation (47%)
Nausea (33%)
Dyspepsia (22%)
Diarrhea (13%)
Anorexia (12%)
Abdominal pain (11%)
Vomiting (7%)
Flatulence (6%)
Tooth disorder (5%)
Gastrointestinal disorder (2%)
Dysphagia (2%)
Esophagitis (1%)
Fatigue (39%)
Weight increase (18%)
Flushing (8%)
Hot flushes (5%)
Chest pain (4%)
Fever (4%)
Allergy (3%)
Pain (3%)
Localised edema (2%)
Chills (2%)
Postural hypotension (6%)
Palpitation (4%)
Tachycardia (4%)
Pharyngitis (14%)
Rhinitis (12%)
Sinusitis (6%)
Coughing (6%)
Bronchospasm (2%)
Epistaxis (2%)
Micturition disorder (14%)
Urinary tract infection (6%)
Micturition frequency (5%)
Urinary retention (2%)
Dysuria (2%)
Cystitis (2%)
Abnormal vision (18%)
Taste perversion (8%)
Tinnitus (6%)
Lacrimation abnormal (3%)
Mydriasis (2%)
Conjunctivitis (1%)
Myalgia (13%)
Back pain (6%)
Arthralgia (3%)
Muscle weakness (1%)
Purpura (3%)
Thirst (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sweating 13.4%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Nausea 16.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Dizziness 17.9%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Tremor 22.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Somnolence 24.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Constipation 25%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Abdominal pain 3.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Dry mouth 42.9%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Insomnia 8%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Asthenia 9.8%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 35
n = 112
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: 35
Sex: M+F
Population Size: 112
Sources:
Insomnia 11%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Abdominal pain 13%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dyspepsia 13%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Aggressive reaction 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anemia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anisocoria 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anxiety 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Asthenia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Blepharospasm 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Confusion 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Depersonalization 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Disorder vestibular 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dyspnea 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Eructation 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Eye allergy 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Fever 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Halitosis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Hot flushes 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Hypertonia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Irritability 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Laryngitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Muscle weakness 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Myoclonus 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Panic reaction 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Paresis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Paresthesia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Pruritus 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sinusitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Skin odor abnormal 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Syncope 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tachycardia 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Ulcerative stomatitis 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Weight increase 2%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Anorexia 22%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Constipation 22%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Headache 28%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tremor 33%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Fatigue 35%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Coughing 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Micturition disorder 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Nervousness 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Otitis media 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Pain 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Palpitation 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Postural hypotension 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Rash 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Taste perversion 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Tinnitus 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Twitching 4%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dizziness 41%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Somnolence 46%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Dry mouth 63%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Abnormal vision 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Allergy 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Bronchospasm 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Chest pain 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Diarrhea 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Flushing 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Memory impairment 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Rhinitis 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Urinary retention 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Vomiting 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Weight decrease 7%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Nausea 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sleep disorder 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Sweating increased 9%
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, Children and Adolescents
n = 46
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: Children and Adolescents
Sex: M+F
Population Size: 46
Sources:
Conjunctivitis 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Esophagitis 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Muscle weakness 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Panic reaction 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urticaria 1%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Abdominal pain 11%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Increased appetite 11%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Anorexia 12%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Rhinitis 12%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Diarrhea 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Myalgia 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Myoclonus 13%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Micturition disorder 14%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pharyngitis 14%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Abnormal vision 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Nervousness 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Weight increase 18%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Acne 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Bronchospasm 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Chills 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Cystitis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Depersonalization 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dermatitis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dry skin 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dysphagia 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dysuria 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Emotional lability 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Epistaxis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Gastrointestinal disorder 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Irritability 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Localised edema 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Mydriasis 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Thirst 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urinary retention 2%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Influence on libido 21%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dyspepsia 22%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Insomnia 25%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sweating increased 29%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Agitation 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Allergy 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Arthralgia 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Confusion 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dreaming abnormal 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Lacrimation abnormal 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Migraine 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pain 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Psychosomatic disease 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Purpura 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Speech disorder 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Yawning 3%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Nausea 33%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Fatigue 39%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Chest pain 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Fever 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Hypertonia 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Palpitation 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sleep disorder 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tachycardia 4%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Constipation 47%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Concentration impaired 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Depression 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Hot flushes 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Micturition frequency 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tooth disorder 5%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Headache 52%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dizziness 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Somnolence 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tremor 54%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Back pain 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Coughing 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Flatulence 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Postural hypotension 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Pruritus 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Sinusitis 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Tinnitus 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Urinary tract infection 6%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Twitching 7%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Vomiting 7%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Flushing 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Rash 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Taste perversion 8%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Dry mouth 84%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Anxiety 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Memory impairment 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Paresthesia 9%
250 mg 1 times / day multiple, oral (max)
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, adult
n = 322
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 322
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
no
no
no
no
yes
yes
yes
yes (pharmacogenomic study)
Comment: administration of clomipramine to a CYP2C19 intermediate metabolizer resulted in elevated serum trough concentrations
yes
yes (pharmacogenomic study)
Comment: administration of clomipramine to a CYP2D6 intermediate metabolizer resulted in elevated serum trough concentrations
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Pharmacotherapy for severe aggression in a child with autism: "open label" evaluation of multiple medications on response frequency and intensity of behavioral intervention.
2000 Sep-Dec
Trichotillomania. Presentation, etiology, diagnosis and therapy.
2001
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats.
2001
Pharmacological characterization of the serotonin transporter in young and elderly subjects.
2001
Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans.
2001
Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder(OCD): form and control.
2001
Development of a depersonalization severity scale.
2001 Apr
[Current drug treatment. Effects of antidepressive agents in nervous and stress-related disorders].
2001 Apr 2
Interaction of psychotropic drugs with monoamine oxidase in rat brain.
2001 Aug
Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
Altered dendritic spine density in animal models of depression and in response to antidepressant treatment.
2001 Dec 1
A review of the pharmacological and clinical profile of mirtazapine.
2001 Fall
Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation.
2001 Feb
Selected tricyclic antidepressant ingestions involving children 6 years old or less.
2001 Feb
Auditory P300 event related potential and serotonin reuptake inhibitor treatment in obsessive-compulsive disorder patients.
2001 Feb 14
Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury.
2001 Jan
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
2001 Jul
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
2001 Jul
The critical window of brain development from susceptive to insusceptive. Effects of clomipramine neonatal treatment on sexual behavior.
2001 Jul 23
[Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study].
2001 Jul-Aug
Digitalis intoxication misdiagnosed as depression--revisited.
2001 Jul-Aug
Clomipramine--beyond separation anxiety.
2001 Jul-Aug
Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines.
2001 Jun
Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment.
2001 Jun
Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments?
2001 Jun
Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies.
2001 Jun
The exploding head syndrome.
2001 Jun
Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
2001 Mar
A dose-finding and discontinuation study of clomipramine in panic disorder.
2001 Mar
[Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease. Apropos of a case].
2001 Mar-Apr
Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
2001 May
[Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
2001 May-Jun
[Narcolepsy in a prepubertal boy].
2001 Nov
Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters.
2001 Nov
Adults with early-onset obsessive-compulsive disorder.
2001 Nov
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells.
2001 Oct
Clinical predictors of drug response in obsessive-compulsive disorder.
2001 Oct
Clomipramine discontinuation-emergent dystonia.
2001 Oct
Ping-pong gaze in combined intoxication with tranylcypromine, thioridazine, and clomipramine.
2001 Oct-Dec
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.
2001 Sep
Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
2001 Sep
[Chronic discomfort with dentures - successful treatment with clomipramine].
2001 Sep
Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?
2001 Sep
Comment: serotonin syndrome and 5-HT2A antagonism.
2001 Sep
HPLC of basic drugs on microparticulate strong cation-exchange materials - a review.
2001 Sep 15
Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors.
2001 Sep 15
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum.
2001 Sep 25
Effects of clomipramine on Trypanosoma cruzi infection in mice.
2001 Sep-Oct
Patents

Sample Use Guides

Adults: Treatment should be initiated at a dosage of 25 mg daily and gradually increased, as tolerated, to approximately 100 mg during the first 2 weeks. During initial titration, the drug should be given in divided doses with meals to reduce gastrointestinal side effects. Thereafter, the dosage may be increased gradually over the next several weeks, up to a maximum of 250 mg daily.
Route of Administration: Oral
In Vitro Use Guide
The effect of clomipramine, at concentrations of 10(-7)M to 10(-4)M, was studied in vitro on the uptake of 5-hydroxytryptamine and dopamine uptake in human platelet-rich plasma.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:21:09 GMT 2023
Edited
by admin
on Fri Dec 15 16:21:09 GMT 2023
Record UNII
2LXW0L6GWJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOMIPRAMINE HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
CLOMIPRAMINE HYDROCHLORIDE [USP-RS]
Common Name English
Clomipramine hydrochloride [WHO-DD]
Common Name English
5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 3-CHLORO-10,11-DIHYDRO-N,N-DIMETHYL-, MONOHYDROCHLORIDE
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [USAN]
Common Name English
NSC-759323
Code English
CLOMIPRAMINE HCL
Common Name English
G-34586
Code English
3-CHLORO-5-(3-(DIMETHYLAMINO)PROPYL)-10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPINE MONOHYDROCHLORIDE
Systematic Name English
CLOMIPRAMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [MART.]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [MI]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [VANDF]
Common Name English
CLOMIPRAMINE HYDROCHLORIDE [JAN]
Common Name English
ANAFRANIL
Brand Name English
G 34586
Code English
Classification Tree Code System Code
NCI_THESAURUS C94727
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID3042633
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
CHEBI
47780
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
DRUG BANK
DBSALT000028
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
CHEBI
3755
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
EVMPD
SUB01361MIG
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
DAILYMED
2LXW0L6GWJ
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
NSC
759323
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
NCI_THESAURUS
C47458
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
RS_ITEM_NUM
1140247
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL415
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
PUBCHEM
68539
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
RXCUI
81984
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY RxNorm
CAS
17321-77-6
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
MERCK INDEX
m3648
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
241-344-3
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
FDA UNII
2LXW0L6GWJ
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
SMS_ID
100000090503
Created by admin on Fri Dec 15 16:21:09 GMT 2023 , Edited by admin on Fri Dec 15 16:21:09 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY